Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing next-generation medicines to address immune-mediated and metabolic diseases. Its lead program Reproxalap is in late-stage development for dry eye disease and allergic conjunctivitis, with additional candidates targeting retinal and systemic inflammatory conditions. The company maintains a broader portfolio that includes compounds such as ADX248, ADX743, ADX631, ADX246, ADX629, and ADX2191, and is exploring therapies for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, Sjögren-Larsson Syndrome, other retinal diseases, autoimmune diseases, and cancer.
Top Stages
1 past transactions
Helio Vision
Acquisition in 2019
Helio Vision, Inc. is a biotechnology company based in Waltham, Massachusetts, founded in 2016. The company focuses on developing therapies for proliferative vitreoretinopathy (PVR), a condition characterized by abnormal scarring that can result in blindness following retinal detachment. Co-founded by physicians from the Massachusetts Eye and Ear Infirmary, Helio Vision is pioneering a treatment that utilizes sustained intravitreal exposure to methotrexate, a drug known for its anti-proliferative and anti-inflammatory properties. This innovative approach aims to prevent the post-operative scarring cycle associated with retinal surgeries, thereby addressing a critical need in eye care for patients affected by these rare fibroproliferative disorders. As of early 2019, Helio Vision operates as a subsidiary of Aldeyra Therapeutics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.